Vorapaxar
98%
- Product Code: 54966
CAS:
900161-12-8
| Molecular Weight: | 490.591 g./mol | Molecular Formula: | C₂₉H₃₄N₂O₅ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | room temperature, dry |
Product Description:
Vorapaxar is primarily used in the prevention of thrombotic cardiovascular events. It is specifically indicated for reducing the risk of heart attack, stroke, and cardiovascular death in patients with a history of heart attack or peripheral arterial disease. The drug works by inhibiting the protease-activated receptor-1 (PAR-1), which plays a key role in platelet activation and clot formation. This targeted action helps to prevent the formation of new blood clots without significantly increasing the risk of bleeding, making it a valuable option for patients who are at high risk of recurrent cardiovascular events. It is often prescribed in combination with other antiplatelet therapies, such as aspirin and clopidogrel, to enhance its efficacy. However, careful patient selection is crucial due to the potential risk of bleeding, particularly in individuals with a history of stroke or transient ischemic attack.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | white to off-white solid |
| PURITY | 97.5-100 |
| Infrared spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.200 | 10-20 days | ฿8,600.00 |
+
-
|
| 1.000 | 10-20 days | ฿28,990.00 |
+
-
|
Vorapaxar
Vorapaxar is primarily used in the prevention of thrombotic cardiovascular events. It is specifically indicated for reducing the risk of heart attack, stroke, and cardiovascular death in patients with a history of heart attack or peripheral arterial disease. The drug works by inhibiting the protease-activated receptor-1 (PAR-1), which plays a key role in platelet activation and clot formation. This targeted action helps to prevent the formation of new blood clots without significantly increasing the risk of bleeding, making it a valuable option for patients who are at high risk of recurrent cardiovascular events. It is often prescribed in combination with other antiplatelet therapies, such as aspirin and clopidogrel, to enhance its efficacy. However, careful patient selection is crucial due to the potential risk of bleeding, particularly in individuals with a history of stroke or transient ischemic attack.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :